Mr. Damien McCallion:

The bulk of the cost in terms of HSE investment to date has been in Irish laboratories. In case there is any doubt, the bulk of that investment has been in our acute hospitals or laboratories such as the National Virus Reference Laboratory and other associated laboratories. As stated earlier by Ms O'Beirne, we are developing a strategy that seeks to beef up the capacity on-island to cater for the flu season next year, for example, other potential surges and how to build on that in a sustainable way. It is not, unfortunately, just a case of purchasing the test. It is about staffing, the logistics, the infrastructure, the buildings and the IT, which is crucial. Earlier, a Deputy mentioned the learning. Not having all of that technology and building on it as we moved through this crisis has been one of the biggest challenges. We are continuing to invest in trying to improve the turnaround times through all of those small process changes. There is very significant investment. The bulk of the costs set out in the paper and provided to members are in regard to our own services on-island.